Zimmer Biomet Holdings, Inc.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. carries a market capitalization of 12.72B, placing it among publicly traded companies globally. Its enterprise value stands at 18.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zimmer Biomet Holdings, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. has 190.56M shares outstanding.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. trades at a trailing price-to-earnings ratio of 20.04. The price-to-sales ratio is 1.90, and the price-to-book ratio stands at 1.25.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. trades at an EV/EBITDA multiple of 9.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.94 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Zimmer Biomet Holdings, Inc. trades at an EV/FCF ratio of 13.82, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 18.44B versus a market cap of 12.72B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.20, indicating elevated leverage, while an interest coverage ratio of 8.01 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zimmer Biomet Holdings, Inc. posted a return on equity (ROE) of 6.41, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.18 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.25, useful for judging operating efficiency across full business cycles. The company generates approximately 404,333.17 in revenue per employee across its workforce of 17,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.09 indicates how many times Zimmer Biomet Holdings, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zimmer Biomet Holdings, Inc. recorded 102.27M in income tax expense. That works out to an effective tax rate of 13.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 754.19M, leaving 651.60M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Zimmer Biomet Holdings, Inc.'s stock has declined approximately 8.42% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Zimmer Biomet Holdings, Inc. generated 6.87B in revenue and converted that into 651.60M in net income, yielding earnings per share of 3.32. EBITDA reached 1.87B, while operating income came in at 1.12B.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. holds 331.21M in cash and equivalents against 6.04B in total debt, resulting in a net debt position of 5.71B. Total book value stands at 10.20B, with working capital of 1.68B providing operational flexibility.

Zimmer Biomet Holdings, Inc. produced 1.41B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -275.87M in capital expenditures, free cash flow totaled 1.13B - equivalent to 5.79 per share.

Over the twelve months ended June 30, 2026, Zimmer Biomet Holdings, Inc. posted a gross margin of 69.87, reflecting its pricing power and cost economics. The operating margin of 16.34 and net profit margin of 9.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Zimmer Biomet Holdings, Inc. paid dividends of 0.78 per share. The dividend payout ratio of 23.34 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.64, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zimmer Biomet Holdings, Inc. shareholders.

As of June 30, 2026, Zimmer Biomet Holdings, Inc. has an Altman Z-Score of 4.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.